NASDAQ:IMNM

Immunome (IMNM) Stock Price, News & Analysis

Immunome logo
$17.12 -0.49 (-2.79%)
As of 03:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Immunome Stock (NASDAQ:IMNM)

Advanced

Key Stats

Today's Range
$16.78
▼
$18.16
50-Day Range
$16.47
▼
$26.81
52-Week Range
$16.41
▼
$30.06
Volume
696,805 shs
Average Volume
1.37 million shs
Market Capitalization
$2.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.85
Consensus Rating
Moderate Buy

Company Overview

Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need.

The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.

Immunome became a publicly traded company in 2023 following a merger with Morphimmune and a combination with Ayala Pharmaceuticals. The company is based in the United States and conducts research and clinical development, with trials that may involve sites in multiple countries.

AI Generated. May Contain Errors.

Immunome Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

IMNM MarketRank™: 
2.497015519295 of 5 stars

Immunome scored higher than 50% of companies evaluated by MarketBeat, and ranked 541st out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immunome has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on no strong buy ratings, 14 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Immunome has a consensus price target of $33.85, representing about 94.4% upside from its current price of $17.41.

  • Amount of Analyst Coverage

    Immunome has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Immunome's stock forecast and price target.
  • Earnings Growth

    Earnings for Immunome are expected to decrease in the coming year, from ($2.62) to ($2.92) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immunome is -6.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immunome is -6.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immunome has a P/B Ratio of 4.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    15.35% of the float of Immunome has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunome has a short interest ratio ("days to cover") of 12.77, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Immunome has recently decreased by 6.41%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Immunome does not currently pay a dividend.

  • Dividend Growth

    Immunome does not have a long track record of dividend growth.

  • News Sentiment

    Immunome has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for Immunome this week, compared to 4 articles on an average week.
  • Search Interest

    Only 2 people have searched for IMNM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Immunome to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Immunome insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $334,224.00 in company stock.

  • Percentage Held by Insiders

    7.21% of the stock of Immunome is held by insiders.

  • Percentage Held by Institutions

    44.58% of the stock of Immunome is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Immunome's insider trading history.
Receive IMNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IMNM Stock News Headlines

Immunome FY2026 Earnings Forecast Decreased by HC Wainwright
Don't lose access to this
Ian Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall. The free download walks through strategies for navigating the options market, but the window to claim it is closing soon.tc pixel
Research Analysts Offer Predictions for Immunome Q1 Earnings
Immunome (NASDAQ:IMNM) Stock Price Target Cut by Piper Sandler
See More Headlines

IMNM Stock Analysis - Frequently Asked Questions

Immunome's stock was trading at $21.48 at the beginning of the year. Since then, IMNM stock has decreased by 18.9% and is now trading at $17.41.

Immunome, Inc. (NASDAQ:IMNM) released its earnings results on Monday, November, 9th. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by $0.14.

Immunome (IMNM) raised $39 million in an IPO on Thursday, October 1st 2020. The company issued 3,250,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Chardan acted as the underwriters for the IPO.

Immunome's top institutional shareholders include State Street Corp (3.95%), Goldman Sachs Group Inc. (1.21%), Nan Fung Trinity HK Ltd. (0.55%) and Marshall Wace LLP (0.44%). Insiders that own company stock include Clay B Siegall, Philip Wagenheim, Isaac Barchas, Jack Higgins, Max Rosett, Kinney Horn, Jean Jacques Bienaime, Philip Tsai and Robert Lechleider.
View institutional ownership trends
.

Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunome investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Broadcom (AVGO), Tesla (TSLA), Micron Technology (MU) and JPMorgan Chase & Co. (JPM).

Company Calendar

Last Earnings
11/09/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:IMNM
CIK
1472012
Fax
N/A
Employees
177
Year Founded
2008

Price Target and Rating

High Price Target
$40.00
Low Price Target
$23.00
Potential Upside/Downside
+98.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.81
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.64)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$212.39 million
Net Margins
N/A
Pretax Margin
-5,593.85%
Return on Equity
-51.33%
Return on Assets
-47.63%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.66
Quick Ratio
15.08

Sales & Book Value

Annual Sales
$6.94 million
Price / Sales
290.68
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.85 per share
Price / Book
4.44

Miscellaneous

Outstanding Shares
118,070,000
Free Float
109,560,000
Market Cap
$2.02 billion
Optionable
Optionable
Beta
2.68

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:IMNM) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners